Tenofovir Disoproxil
- TRADE NAMES: Atripla (Gilead); Complera (Gilead); Truvada (Gilead); Viread (Gilead)
- INDICATIONS: HIV infection in combination with at least two other antiretroviral agents
- CLASS: Antiretroviral, Covid-19 putative drug, Nucleoside analog reverse transcriptase inhibitor
- HALF-LIFE: 12–18 hours
Acyclovir, Adefovir, Atazanavir, Cidofovir, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Darunavir, Didanosine, Ganciclovir, High-fat foods, Indinavir, Ledipasvir & Sofosbuvir, Lopinavir, Protease inhibitors, Ritonavir, Telaprevir, Tipranavir, Trospium, Valacyclovir, Valganciclovir
PREGNANCY CATEGORY: B
Investigated for treating COVID-19.
Atripla is tenofovir disoproxil, efavirenz and emtricitabine; Complera is tenofovir disoproxil, emtricitabine and rilpivirine; Truvada is tenofovir disoproxil and emtricitabine.
See also separate profile for tenofovir disoproxil in combination with cobicistat, elvitegravir and emtricitabine.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tabs (above) to see a review of tenofovir in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 09/06/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric